Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the
treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia.
Patients will be given a conditioning chemotherapy regimen of fludarabine and
cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.